Robbins LLP Urges NVO Stockholders with Large Losses to Contact the Firm for Information about Leading the Class Action Against Novo Nordisk A/S

Core Viewpoint - A class action has been filed against Novo Nordisk A/S for allegedly misleading investors about its revenue and profit growth potential during the specified period [1][2]. Group 1: Allegations - The complaint alleges that Novo Nordisk overstated its growth potential and failed to disclose the impact of the personalization exception to the compounded GLP-1 exclusion [2]. - It is claimed that the company misrepresented the likelihood of patients transitioning from compounded GLP-1s to its branded alternatives [2]. - The complaint also states that Novo Nordisk significantly overstated the size of the GLP-1 market and its ability to penetrate that market for sustained growth [2]. Group 2: Financial Outlook - On July 29, 2025, Novo Nordisk announced a reduction in its sales and profit outlook, attributing this to lower growth expectations for Wegovy and Ozempic due to persistent use of compounded GLP-1s and increased competition [3]. - Following this announcement, Novo Nordisk's stock price fell from $69.00 per share on July 28, 2025, to $53.94 per share on July 29, 2025 [3]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Novo Nordisk, with a deadline to submit papers to serve as lead plaintiff by September 30, 2025 [4]. - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [4].